CVRx, Inc. CVRX

CVRx, Inc. appointed John Landry as Chief Financial Officer, succeeding Jared Oasheim. Landry will join on Oct. 12, 2026, and assume the CFO role the day after CVRx files its Form 10-Q for the quarter ended Sept. 30, 2026. He has more than two decades of medical-device finance leadership, currently serving as CFO of Nyxoah and formerly of Vapotherm, Salient Surgical Technologies, Bottomline Technologies and others. He led capital raises and the company IPO at Vapotherm and built finance, investor relations and public-company reporting functions. CEO Kevin Hykes says Landry's blend of commercial and capital-markets experience positions CVRx to scale Barostim and expand heart-failure adoption. Oasheim will remain through a transition period. Barostim is FDA-approved for heart failure in the U.S. and has CE Mark in Europe. Brings proven IPO and capital-raising experience to strengthen finance ops and investor relations as Barostim scales.

CVRx secures Devoted Health coverage for Barostim Therapy, expanding reimbursement access for the heart failure treatment. Devoted Health coverage expands Barostim Therapy access and supports CVRx revenue potential.

Jorey Chernett, owner of over 5.5% of CVRx shares, demands the board immediately start a sale process to a strategic acquirer. Major shareholder demand to sell the company signals potential acquisition and strategic change affecting trajectory.

CVRx announced Devoted Health Medicare Advantage coverage for Barostim Therapy. Medicare Advantage coverage expands patient access to Barostim Therapy potentially boosting CVRx revenue.

CVRx targets Barostim growth via expanded coverage and BENEFIT-HF trial launch. Coverage gains plus new trial launch enable major Barostim expansion and adoption.

CVRx held its Q2 2026 earnings call to review financial results, operations and outlook. Quarterly earnings calls deliver financial updates that moderately shape near-term investor sentiment.

CVRx, Inc. released its Q2 2026 earnings call summary covering financial results, operational metrics and business outlook. Quarterly earnings summaries deliver performance data that can moderately influence near-term valuation and sentiment.

CVRx Inc reported Q2 2026 results with sales execution challenges offsetting strong performance in other areas. Sales execution challenges signal operational issues likely to constrain near-term growth without derailing overall trajectory.

CVRx reports Q2 loss but beats revenue estimates. Q2 earnings results directly affect near-term stock valuation and investor sentiment for the company.

CVRx reported Q2 financial results and operational updates during its earnings call, highlighting revenue figures, device sales trends, and forward-looking guidance on commercialization efforts. Quarterly results and guidance provide moderate insight into revenue trajectory and growth plans but do not signal major strategic shifts.

CVRx Inc. reported Q2 earnings with key metrics compared to Wall Street estimates. Quarterly earnings and metric comparisons typically produce short-term share price moves without shifting long-term fundamentals.

CVRx, Inc. released second quarter 2026 financial results and operating performance update. Quarterly financial results update performance metrics that influence near-term investor sentiment and valuation.

CVRx stock rises after Humana grants Medicare coverage for Barostim Therapy. Humana Medicare coverage expands Barostim Therapy access and boosts CVRx revenue prospects.

Analysts issued a financial statement on CVRx, Inc. (NASDAQ:CVRX)'s first-quarter report. Analyst commentary on quarterly financials moderately influences investor sentiment and stock trajectory.

CVRx announces Humana Medicare Advantage coverage policy for Barostim Therapy, enabling access for Humana Medicare Advantage members. Humana Medicare Advantage coverage for Barostim Therapy unlocks reimbursement for millions of patients, significantly boosting CVRx revenue and adoption.

CVRx (CVRX) stock dropped 31.7% in four weeks, but buying the dip is recommended due to strong fundamentals, growth potential, and undervaluation. Recent 31.7% stock decline creates short-term pressure but highlights buying opportunity from solid fundamentals and growth prospects.

CVRx, Inc. released Q1 2026 earnings call results covering financial performance, operational updates and forward guidance. Earnings call delivers core financial metrics and outlook that directly shape stock valuation and investor positioning.

CVRx Inc (CVRX) Q1 2026 earnings call highlights strong U.S. growth and significant market expansion potential. Strong U.S. growth and market expansion potential represent major strategic advancements boosting CVRx's future performance and investor sentiment.

CVRx reported Q1 earnings call highlights, showcasing revenue growth, operational updates, and future guidance amid ongoing commercialization of its Barostim system. Q1 earnings highlights detail financial results and outlook, significantly impacting investor sentiment and market performance.

CVRx, Inc. reported first quarter 2026 financial and operating results. Quarterly financial and operating results directly shape investor sentiment, stock valuation, and future growth expectations for CVRx.

CVRx (CVRX) reported a Q1 net loss but beat revenue estimates. Q1 revenue beat despite net loss indicates moderate positive influence on financial trajectory and investor sentiment.

CVRx enrolls first patient in BENEFIT-HF trial, a landmark study evaluating Barostim therapy in significantly expanded heart failure population. First enrollment in landmark BENEFIT-HF trial expands Barostim to broader heart failure population, positioning CVRx for major regulatory and market growth.

CVRx, Inc. (CVRX) reported preliminary first quarter 2026 financial results. Preliminary quarterly financial results provide critical updates on revenue and performance, significantly influencing investor sentiment and stock trajectory.

CVRx announced late-breaking data and scientific presentations highlighting Barostim outcomes at the THT 2026 Annual Meeting. Late-breaking data presentations on Barostim at a major cardiology meeting signal strong clinical validation that could drive significant investor sentiment and stock performance.

CVRx Inc. reported robust Q4 2025 revenue growth and unveiled strategic expansions during its earnings call, navigating challenges while advancing core operations. Revenue growth and strategic expansions represent major positive developments likely to boost financial trajectory and investor confidence.

Analysts revise estimates for CVRx, Inc. (NASDAQ:CVRX) after full-year results. Analyst updates following full-year results signal potential shifts in financial outlook and investor sentiment for CVRx.

CVRx, Inc. reported its Q4 2025 earnings, highlighting significant revenue growth and advancements in product development. The company emphasized its commitment to innovation in cardiovascular therapies and outlined strategic plans for market expansion. Key financial metrics showed improved performance compared to previous quarters, indicating a positive trajectory for the company. Management expressed optimism about future prospects and ongoing clinical trials that could enhance product offerings. Significant revenue growth and strategic plans for market expansion are likely to impact future performance.

CVRx, Inc. reported its Q4 earnings, highlighting significant growth in revenue and an increase in product demand. The company emphasized advancements in its technology and expansion into new markets, which are expected to drive future performance. Management provided optimistic guidance for the upcoming quarters, citing strong interest from healthcare providers and patients. The earnings call also addressed ongoing regulatory efforts and strategic partnerships aimed at enhancing market presence. Significant growth in revenue and product demand, along with strategic advancements, are likely to impact future performance positively.

CVRx, Inc. reported its financial and operating results for the fourth quarter and full year of 2025, highlighting key metrics such as revenue growth and operational achievements. The company continues to focus on its innovative therapies for heart failure, demonstrating progress in clinical trials and market expansion efforts. Management expressed optimism about future prospects and strategic initiatives aimed at enhancing shareholder value. Significant revenue growth and operational achievements indicate a strong trajectory for the company's future performance.

CVRx, Inc. reported its Q4 earnings, highlighting key financial metrics and performance indicators. The company showed growth in revenue and provided insights into its strategic initiatives and market positioning. Management discussed future outlook and potential challenges, emphasizing ongoing efforts to enhance product offerings and expand market reach. The earnings report indicates moderate growth and strategic initiatives that may influence financial performance but are balanced by potential challenges.